Truist Securities analyst Les Sulewski reiterated a Buy rating on Collegium Pharmaceutical (NASDAQ: COLL).The analyst commented: "We like the risk/reward ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments